Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2026-03-17 Proxy Solicitation & In…
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Relazione Illustrativa sulla nomina del Consiglio di Amministrazione
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an 'Illustrative Report of the Board of Directors' regarding items on the agenda for an upcoming Ordinary Shareholders' Meeting (specifically the appointment of the Board of Directors). This type of document is a standard proxy statement or information circular provided to shareholders to explain the proposals they will vote on at the meeting. In the context of the provided categories, this falls under 'Proxy Solicitation & Information Statement' (PSI), as it provides the necessary information for shareholders to exercise their voting rights for the upcoming AGM.
2026-03-17 Italian
NOTICE OF CALLING OF THE ORDINARY SHAREHOLDERS’ MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Calling of the Ordinary Shareholders' Meeting' for Pharmanutra S.p.A. It outlines the agenda, voting procedures, and instructions for shareholders to participate via a designated representative. This document is a classic proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2026-03-17 English
Avviso di convocazione Assemblea ordinaria degli azionisti
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an official 'Avviso di convocazione di Assemblea ordinaria' (Notice of Call for an Ordinary Shareholders' Meeting) for Pharmanutra S.p.A. It outlines the agenda, voting procedures, and instructions for shareholders to participate via a designated representative. This document is a formal proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2026-03-17 Italian
PHARMANUTRA - PHN: FY 2025 FINANCIAL RESULTS PRESENTATION
Investor Presentation Classification · 1% confidence The document is a detailed presentation titled 'FY 2025 FINANCIAL RESULTS' for Pharmanutra S.p.A. It contains comprehensive financial data, including profit and loss statements, balance sheets, cash flow analysis, and business highlights. It is clearly intended for investors and analysts, as indicated by the disclaimer and the structured presentation format. It is not a full 10-K annual report, but rather an investor-facing presentation summarizing the annual financial performance.
2026-03-17 English
PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025
Earnings Release Classification · 1% confidence The document is a press release from Pharmanutra S.p.A. announcing the approval of its draft and consolidated financial statements for the fiscal year ending December 31, 2025. It contains key financial highlights (revenues, EBITDA, net result, EPS), dividend proposals, and management commentary. While it discusses financial results, it is an initial announcement (Earnings Release) rather than the full 10-K or Annual Report document itself. It follows the standard format for an earnings release, providing a summary of performance indicators and business outlook. FY 2025
2026-03-17 English
PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025
Earnings Release Classification · 1% confidence The document is a press release issued by Pharmanutra S.p.A. on March 17, 2026, announcing that the Board of Directors has approved the draft financial statements and consolidated financial statements for the year ended December 31, 2025. It provides key financial highlights (revenue, EBITDA, net income, EPS), dividend proposals, and a summary of business performance. While it contains financial data, it is an initial announcement of the results rather than the full 10-K/Annual Report document itself. Therefore, it is classified as an Earnings Release. FY 2025
2026-03-17 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.